| ABSTRACT Objective:To evaluate the clinical safety on puerarin injection in cardiovascular system. Methods:Collecting clinical research literature by searching CNKI, VIP, WanFang Data, SinoMed, Medline, EMbase, CENTRAL, PubMed,Web of Science that officially published about adverse reactions of cardiovascular system. According to the inclusion and exclusion criteria, making a Meta analysis of adverse reaction rate by using RevMan 5.3 software. Results: Seventeen studies were analysed. Compared with control group that did not use puerarin injection, puerarin injection could increased the risk of adverse reactions of cardiovascular system [RR=2.81, 95%CI (1.50, 5.24), P=0.001]. Subgroup analysis showed that risk of adverse reactions of cardiovascular system in the angina pectoris subgroup,≥400 mg·d-1 subgroups, ≥14 d subgroups was significantly higher than the control group (P＜0.05). The risk of adverse reactions of cardiovascular system in ＜400 mg·d-1 subgroup, ＜14 d subgroup, cerebral infarction subgroup and other diseases subgroup was no significant difference compared to the control group (P＞0.05).Conclusion:The adverse reaction rate of cardiovascular system was higher than the control group. In the treatment of angina and the dose ≥400mg·d 1, the course of treatment ≥14d, the clinicians needed to pay attention to drug safety, and reduce the risk of cardiovascular adverse reations. |
